Mitigating Health Risks of Prescription Drugs: Lessons From FDA Oversight of Opioid Products

JAMA. 2019 Feb 19;321(7):651-653. doi: 10.1001/jama.2019.0236.

Authors

Ameet Sarpatwari¹, Gregory Curfman²

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Deputy Editor.

PMID: 30778584
DOI: 10.1001/jama.2019.0236

No abstract available

Publication types

Editorial
Comment

MeSH terms

Analgesics, Opioid
Fentanyl*
Prescription Drug Misuse
Prescription Drugs*
Risk Evaluation and Mitigation

Substances

Analgesics, Opioid
Prescription Drugs
Fentanyl